Patent protection secured in key markets

Aptahem has established a comprehensive knowledge management system through which new ideas, methods and results are systematically codified. The company’s intellectual property portfolio consists of both approved patents and filed patent applications based on unique new chemical compounds in the form of unique RNA aptamer-based drug candidates. The drug candidates are protected by the strongest form of patent protection in the pharmaceutical industry, i.e. compound matter patent.

For new patentable technology, Aptahem strategically plans to apply for patents in countries that are expected to become key markets for the company in the future. Currently, the following markets are being considered: Europe, the US, Canada, China, Japan and India. The company intends to apply for additional patents in the event that Aptahem considers that the company should strengthen the intellectual property portfolio further.

Aptahem’s intellectual property rights portfolio currently consists of two patent families that are fully-owned by the company. First patent family, as mentioned above, and the second family was filed based on the therapeutic applications and mechanism of the company’s lead candidate, Apta-1. Patent family 2 has been approved in several strategically important geographical areas, and is pending in a few others. This patent family will be updated as new results are collected, which strenghthens the protection further.

Also, new patent opportunities are constantly investigated by the company.